HK1211933A1 - Haptens of olanzipine - Google Patents
Haptens of olanzipineInfo
- Publication number
- HK1211933A1 HK1211933A1 HK15112822.2A HK15112822A HK1211933A1 HK 1211933 A1 HK1211933 A1 HK 1211933A1 HK 15112822 A HK15112822 A HK 15112822A HK 1211933 A1 HK1211933 A1 HK 1211933A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- olanzipine
- haptens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261691454P | 2012-08-21 | 2012-08-21 | |
| PCT/US2013/055700 WO2014031587A1 (en) | 2012-08-21 | 2013-08-20 | Haptens of olanzipine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1211933A1 true HK1211933A1 (en) | 2016-06-03 |
Family
ID=49081007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15112822.2A HK1211933A1 (en) | 2012-08-21 | 2015-12-30 | Haptens of olanzipine |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9303041B2 (tr) |
| EP (2) | EP2888269B1 (tr) |
| JP (3) | JP6171014B2 (tr) |
| CN (1) | CN104854110B (tr) |
| AU (1) | AU2013306018B2 (tr) |
| CA (1) | CA2882454C (tr) |
| ES (1) | ES2701062T3 (tr) |
| HK (1) | HK1211933A1 (tr) |
| PL (1) | PL2888269T3 (tr) |
| PT (1) | PT2888269T (tr) |
| TR (1) | TR201816378T4 (tr) |
| WO (1) | WO2014031587A1 (tr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882596C (en) | 2012-08-21 | 2019-05-14 | Ortho-Clinical Diagnostics, Inc. | Antibodies to olanzapine and use thereof |
| JP6374387B2 (ja) | 2012-08-21 | 2018-08-15 | ヤンセン ファーマシューティカ エヌ．ベー． | リスペリドンハプテンへの抗体及びその使用 |
| CN108484496B (zh) | 2012-08-21 | 2022-03-22 | 詹森药业有限公司 | 阿立哌唑半抗原及其在免疫测定中的应用 |
| TR201910347T4 (tr) | 2012-08-21 | 2019-07-22 | Janssen Pharmaceutica Nv | Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı. |
| WO2014031587A1 (en) * | 2012-08-21 | 2014-02-27 | Janssen Pharmaceutica Nv | Haptens of olanzipine |
| AU2013305907B2 (en) | 2012-08-21 | 2018-01-18 | Saladax Biomedical Inc. | Antibodies to quetiapine and use thereof |
| AU2013305904B2 (en) | 2012-08-21 | 2017-08-17 | Saladax Biomedical Inc. | Antibodies to quetiapine haptens and use thereof |
| TR201816416T4 (tr) | 2012-08-21 | 2018-11-21 | Janssen Pharmaceutica Nv | Risperidona yönelik antikorlar ve bunların kullanımı. |
| ES2666000T3 (es) | 2012-08-21 | 2018-04-30 | Janssen Pharmaceutica, N.V. | Anticuerpos para aripiprazol y uso de los mismos |
| JP2015529199A (ja) | 2012-08-21 | 2015-10-05 | オルソ−クリニカル ダイアグノスティクス，インコーポレイティド | パリペリドンハプテンに対する抗体及びその使用 |
| US9465041B2 (en) | 2012-08-21 | 2016-10-11 | Janssen Pharmaceutica Nv | Antibodies to paliperidone and use thereof |
| JP6389176B2 (ja) | 2012-08-21 | 2018-09-12 | ヤンセン ファーマシューティカ エヌ．ベー． | アリピプラゾールハプテンに対する抗体及びその使用 |
| EP3390455A1 (en) | 2015-12-17 | 2018-10-24 | Janssen Pharmaceutica NV | Antibodies to quetiapine and use thereof |
| AU2016372069A1 (en) | 2015-12-17 | 2018-06-07 | Saladax Biomedical Inc. | Antibodies to risperidone and use thereof |
| CN110938082A (zh) * | 2019-10-30 | 2020-03-31 | 杭州博拓生物科技股份有限公司 | 一种奥氮平人工抗原及其制备方法 |
| CN110950808A (zh) * | 2019-10-30 | 2020-04-03 | 杭州博拓生物科技股份有限公司 | 一种氯氮平人工抗原及其制备方法 |
| CN114685477B (zh) * | 2020-12-25 | 2023-11-17 | 长沙博源医疗科技有限公司 | 一种利奈唑胺衍生物、免疫原、抗利奈唑胺特异性抗体及其制备方法与应用 |
| CN114685527B (zh) * | 2020-12-25 | 2024-03-05 | 长沙博源医疗科技有限公司 | 一种奥氮平衍生物、免疫原、抗奥氮平特异性抗体及其制备方法与应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022780A (en) | 1973-03-06 | 1977-05-10 | Imperial Chemical Industries Limited | Process for the manufacture of indole derivatives |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| AU668159B2 (en) | 1992-05-29 | 1996-04-26 | Lilly Industries Limited | Pharmaceutical compounds |
| US6034078A (en) | 1992-05-29 | 2000-03-07 | Eli Lilly And Company Limited | Thienobenzodiazepine compounds |
| ATE176329T1 (de) * | 1992-06-26 | 1999-02-15 | Johnson & Johnson Clin Diag | Immunotests unter verwendung von markierten thyronin-analogen |
| US5395933A (en) * | 1992-08-07 | 1995-03-07 | Eastman Kodak Company | Carbamazepine hapten analogues |
| UA76708C2 (uk) * | 1999-12-08 | 2006-09-15 | Сінгента Патисипейшонс Аг | Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду |
| US6958156B2 (en) | 2000-12-15 | 2005-10-25 | Vyrex Corporation | Isoflavone derivatives |
| JP2005533009A (ja) * | 2002-03-28 | 2005-11-04 | イーライ・リリー・アンド・カンパニー | ピペラジン置換されたアリールベンゾジアゼピン類およびそのドーパミン受容体アンタゴニストとしての精神病性障害の処置のための使用 |
| AU2003264915A1 (en) * | 2002-08-05 | 2004-02-25 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines |
| CA2538745A1 (en) | 2003-09-23 | 2005-03-31 | Fermion Oy | Preparation of quetiapine |
| EP2266622A3 (en) * | 2004-08-26 | 2012-06-20 | Piramal Life Sciences Limited | Prodrugs containing novel bio-cleavable linkers |
| TW200616604A (en) * | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| JP2010540920A (ja) * | 2007-09-27 | 2010-12-24 | ノバルティス アーゲー | 薬物モニタリングアッセイ |
| US20100069356A1 (en) | 2008-09-17 | 2010-03-18 | Auspex Pharmaceuticals, Inc. | Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors |
| MX2011003598A (es) | 2008-10-14 | 2011-04-27 | Astrazeneca Ab | Compuestos heteroaromaticos espirociclicos, fusionados, para el tratamiento de infecciones bacterianas. |
| EP2194048A1 (en) | 2008-12-02 | 2010-06-09 | Dirk Sartor | Nitrate esters for the treatment of vascular and metabolic diseases |
| AU2010336981B2 (en) | 2009-12-31 | 2014-04-10 | Kempharm, Inc. | Amino acid conjugates of quetiapine, process for making and using the same |
| EP2544536B1 (en) | 2010-03-11 | 2018-12-12 | Kempharm, Inc. | Fatty acid conjugates of quetiapine, process for making and using the same |
| US8088594B2 (en) | 2010-03-16 | 2012-01-03 | Saladax Biomedical Inc. | Risperidone immunoassay |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| US8623324B2 (en) | 2010-07-21 | 2014-01-07 | Aat Bioquest Inc. | Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates |
| JP5757497B2 (ja) * | 2010-10-06 | 2015-07-29 | 公立大学法人大阪府立大学 | シガトキシン類ｃｔｘ１ｂおよび５４−デオキシ−ｃｔｘ１ｂを認識するモノクローナル抗体およびそれを用いるシガトキシン類検出キット |
| AU2012351747B2 (en) * | 2011-12-15 | 2016-05-12 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
| WO2014031587A1 (en) * | 2012-08-21 | 2014-02-27 | Janssen Pharmaceutica Nv | Haptens of olanzipine |
-
2013
- 2013-08-20 WO PCT/US2013/055700 patent/WO2014031587A1/en active Application Filing
- 2013-08-20 PL PL13753774T patent/PL2888269T3/pl unknown
- 2013-08-20 TR TR2018/16378T patent/TR201816378T4/tr unknown
- 2013-08-20 AU AU2013306018A patent/AU2013306018B2/en active Active
- 2013-08-20 ES ES13753774T patent/ES2701062T3/es active Active
- 2013-08-20 CA CA2882454A patent/CA2882454C/en active Active
- 2013-08-20 US US13/970,653 patent/US9303041B2/en active Active
- 2013-08-20 CN CN201380054963.3A patent/CN104854110B/zh active Active
- 2013-08-20 PT PT13753774T patent/PT2888269T/pt unknown
- 2013-08-20 EP EP13753774.2A patent/EP2888269B1/en active Active
- 2013-08-20 EP EP18202081.8A patent/EP3492473A1/en active Pending
- 2013-08-20 JP JP2015528568A patent/JP6171014B2/ja active Active
-
2015
- 2015-12-30 HK HK15112822.2A patent/HK1211933A1/xx unknown
-
2017
- 2017-07-03 JP JP2017130471A patent/JP6423490B2/ja active Active
-
2018
- 2018-10-18 JP JP2018196525A patent/JP6763000B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019034955A (ja) | 2019-03-07 |
| ES2701062T3 (es) | 2019-02-20 |
| PL2888269T3 (pl) | 2019-06-28 |
| CA2882454A1 (en) | 2014-02-27 |
| CN104854110A (zh) | 2015-08-19 |
| EP2888269B1 (en) | 2018-10-24 |
| EP3492473A1 (en) | 2019-06-05 |
| JP6763000B2 (ja) | 2020-09-30 |
| JP2017222671A (ja) | 2017-12-21 |
| JP2015532645A (ja) | 2015-11-12 |
| PT2888269T (pt) | 2019-01-17 |
| JP6423490B2 (ja) | 2018-11-14 |
| WO2014031587A1 (en) | 2014-02-27 |
| EP2888269A1 (en) | 2015-07-01 |
| TR201816378T4 (tr) | 2018-11-21 |
| US20140213766A1 (en) | 2014-07-31 |
| AU2013306018A1 (en) | 2015-03-12 |
| JP6171014B2 (ja) | 2017-07-26 |
| AU2013306018B2 (en) | 2017-08-10 |
| US9303041B2 (en) | 2016-04-05 |
| CA2882454C (en) | 2020-08-11 |
| CN104854110B (zh) | 2016-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1211933A1 (en) | Haptens of olanzipine | |
| HK1214259A1 (zh) | 衍生物 | |
| HK1210172A1 (en) | Crystal of dispiropyrrolidine derivative | |
| HK1211934A1 (en) | Haptens of paliperidone | |
| ZA201406082B (en) | Use of ccr3-inhibitors | |
| HK1203949A1 (en) | Inhibitors of iap iap | |
| PL2642045T3 (pl) | Nachodzący na siebie układ co najmniej dwóch pomostów roboczych | |
| IL236312A0 (en) | Preparation of 18f-flucyclobin | |
| EP2881113A4 (en) | NEW APPLICATION OF POGOSTONE | |
| IL237862A0 (en) | Methods to reduce the formation of scale | |
| EP2892529A4 (en) | USES OF (-) - PERHEXILINE | |
| HK1208553A1 (en) | Certification of origin | |
| ZA201502350B (en) | Solid form of hihydro-pyrido-oxazine derivative | |
| GB201215942D0 (en) | Method of treatent | |
| HUE036665T2 (hu) | Dihidro-pirido-oxazin származék szilárd formái | |
| TWM433525U (en) | Structure of calorifier |